Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Press Release Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Clinical Development Program for Multiple Indications

FirstWordPharmaDecember 03, 2021

Tag: PN-235 , Peptide , Protagonist

PharmaSources Customer Service